491 related articles for article (PubMed ID: 8421204)
21. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
[TBL] [Abstract][Full Text] [Related]
22. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
Biermasz NR; van Dulken H; Roelfsema F
J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
[TBL] [Abstract][Full Text] [Related]
23. Novel features of tumors that secrete both growth hormone and prolactin in acromegaly.
Nyquist P; Laws ER; Elliott E
Neurosurgery; 1994 Aug; 35(2):179-83; discussion 183-4. PubMed ID: 7969823
[TBL] [Abstract][Full Text] [Related]
24. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
Lucas T; Astorga R; Catalá M;
Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
[TBL] [Abstract][Full Text] [Related]
25. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
[TBL] [Abstract][Full Text] [Related]
26. A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin.
De Marinis L; Zuppi P; Valle D; Mancini A; Bianchi A; Lauriola L; Pasquini P; Anile C; Maira G; Giustina A
Horm Metab Res; 2002 Mar; 34(3):137-43. PubMed ID: 11972303
[TBL] [Abstract][Full Text] [Related]
27. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
Jane JA; Starke RM; Elzoghby MA; Reames DL; Payne SC; Thorner MO; Marshall JC; Laws ER; Vance ML
J Clin Endocrinol Metab; 2011 Sep; 96(9):2732-40. PubMed ID: 21715544
[TBL] [Abstract][Full Text] [Related]
28. Transsphenoidal surgery for growth hormone-secreting pituitary adenomas in 130 patients.
Shirvani M; Motiei-Langroudi R
World Neurosurg; 2014 Jan; 81(1):125-30. PubMed ID: 23313263
[TBL] [Abstract][Full Text] [Related]
29. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
30. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
31. Gamma knife radiosurgery for acromegaly--long-term experience.
Jezková J; Marek J; Hána V; Krsek M; Weiss V; Vladyka V; Lisák R; Vymazal J; Pecen L
Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981
[TBL] [Abstract][Full Text] [Related]
32. Factors determining the long-term outcome of surgery for acromegaly.
Osman IA; James RA; Chatterjee S; Mathias D; Kendall-Taylor P
QJM; 1994 Oct; 87(10):617-23. PubMed ID: 7987657
[TBL] [Abstract][Full Text] [Related]
33. Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases.
Baskin DS; Boggan JE; Wilson CB
J Neurosurg; 1982 May; 56(5):634-41. PubMed ID: 7069474
[TBL] [Abstract][Full Text] [Related]
34. Recurrence following transsphenoidal surgery for acromegaly.
Buchfelder M; Brockmeier S; Fahlbusch R; Honegger J; Pichl J; Manzl M
Horm Res; 1991; 35(3-4):113-8. PubMed ID: 1806464
[TBL] [Abstract][Full Text] [Related]
35. Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly.
Bellut D; Hlavica M; Schmid C; Bernays RL
Neurosurg Focus; 2010 Oct; 29(4):E9. PubMed ID: 20887134
[TBL] [Abstract][Full Text] [Related]
36. Evidence supporting surgery as treatment of choice for acromegaly.
Fahlbusch R; Honegger J; Buchfelder M
J Endocrinol; 1997 Oct; 155 Suppl 1():S53-5. PubMed ID: 9389996
[TBL] [Abstract][Full Text] [Related]
37. Transsphenoidal microsurgery in the treatment of acromegaly and gigantism.
Arafah BU; Brodkey JS; Kaufman B; Velasco M; Manni A; Pearson OH
J Clin Endocrinol Metab; 1980 Mar; 50(3):578-85. PubMed ID: 6244327
[TBL] [Abstract][Full Text] [Related]
38. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
39. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study.
Attanasio R; Epaminonda P; Motti E; Giugni E; Ventrella L; Cozzi R; Farabola M; Loli P; Beck-Peccoz P; Arosio M
J Clin Endocrinol Metab; 2003 Jul; 88(7):3105-12. PubMed ID: 12843150
[TBL] [Abstract][Full Text] [Related]
40. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
Sheaves R; Jenkins P; Blackburn P; Huneidi AH; Afshar F; Medbak S; Grossman AB; Besser GM; Wass JA
Clin Endocrinol (Oxf); 1996 Oct; 45(4):407-13. PubMed ID: 8959078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
